Abstract:Gemechu Churiso, 1 Gose Husen, 2 Denebo Bulbula, 2 Lulu Abebe 3 1 Department of Medical Laboratory Sciences, Dilla University, Dilla, Ethiopia; 2 Department of Orthopedic Surgery, Dilla University, Dilla, Ethiopia; 3 Department of Psychiatry, Dilla University, Dilla, Ethiopia Correspondence: Gemechu Churiso, Email Antigen-presenting cells recognize respiratory syncytial virus antigens, and produce cytokines and chemokines that act on immune cells. Dendritic cells play the main role in inflammatory cytokine responses. Similarly, alveolar macrophages produce IFN-β, IFN-α, TNF-α, IL-6, CXCL10, and CCL3, while alternatively activated macrophages differentiate at the late phase, and require IL-13 or IL-4 cytokines. Furthermore, activated NKT cells secrete IL-13 and IL-4 that cause lung epithelial, endothelial and fibroblasts to secrete eotaxin that enhances the recruitment of eosinophil to the lung. CD8 + and CD4 + T cells infection by the virus decreases the IFN-γ and IL-2 production. Despite this, both are involved in terminating virus replication. CD8 + T cells produce a larger amount of IFN-γ than CD4 + T cells, and CD8 + T cells activated under type 2 conditions produce IL-4, down regulating CD8 expression, granzyme and IFN-γ production. Antiviral inhibitors inhibit biological functions of viral proteins. Some of them directly target the virus replication machinery and are effective at later stages of infection; while others inhibit F protein dependent fusion and syncytium formation. TMC353121 reduces inflammatory cytokines, TNF-α, IL-6, and IL-1β and chemokines, KC, IP-10, MCP and MIP1-α. EDP-938 inhibits viral nucleoprotein (N), while GRP-156784 blocks the activity of respiratory syncytial virus ribonucleic acid (RNA) polymerase. PC786 inhibits non-structural protein 1 (NS-1) gene, RANTES transcripts, virus-induced CCL5, IL-6, and mucin increase. In general, it is an immune reaction that is blamed for the disease severity and pathogenesis in respiratory syncytial virus infection. Anti-viral inhibitors not only inhibit viral entry and replication, but also may reduce inflammatory cytokines and chemokines. Many respiratory syncytial virus inhibitors are proposed; however, only palivizumab and ribavirin are approved for prophylaxis and treatment, respectively. Hence, this review is focused on immunity cell responses to respiratory syncytial virus and the role of antiviral inhibitors. Keywords: immune cells, respiratory syncytial virus, antiviral inhibitors Respiratory syncytial virus (RSV) is an enveloped negative sense RNA virus that has trans membrane surface proteins like F, G and SH, and non-glycosylated virion matrix protein (M), proteins associated with RNA to form viral nucleocapsid (P, N, L and M2 open reading frame 1), and other proteins that are non-structural viral products (NS1 and NS2). 1,2 It causes lower respiratory tract infection affecting mostly elder people and children. 3,4 The RSV virus has 2 main subtypes; subtype A and B. 5 Luminal columnar cells, especially ciliated cells, can be affected by RSV, and the virus can be shed solely from the apical surface of ciliated cells and spread to neighbouring cells by the cilial beats. 6 RSV G protein interaction with C-X-C Motif Chemokine Receptor 1 (CXCR1) on the cell surface of human amniotic epithelial cells (HAECs) is very important to the pathogenesis of the virus. It contributed to around 50% of RSV infectivity in these cells. CXCR1 is predominantly detected on the ciliated cells, and the percentage of these receptors is varied from person to person. 7 Infected people show symptoms like cough, sneezing, runny nose, fever, decrease in appetite, and wheezing within 4 to 6 days of infection. 8 The virus can cause severe infection that includes bronchitis, pneumonia, inflammation of the small airways in the lung, and is common in children younger than one year of age. Older adults and infants earlier than six months of age may need hospitalization and additional oxygen or intubation. 9 Innate and adaptive immunities are induced during RSV infection. Innate immune cells and other virally infected cells secret inflammatory cytokines, which attract and activate immune cells that induce acute inflammation that helps virus clearance. 3 Cellular immunities are very important to clear the RSV infection; 10 unlike virus-neutralizing antibodies that are induced and suboptimal during initial infection and wanes over time. Despite this, re-infection with the virus is common. Even though cellular immunities are very important for the clearance of the virus, they can cause serious lower respiratory tract bronchitis immune pathogenesis. 11</su -Abstract Truncated-

Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection

MAVS Deficiency Is Associated With a Reduced T Cell Response Upon Secondary RSV Infection in Mice

[Airway Inflammation Induced by Poly(I:C) Stimulation in the Late Stage of Respiratory Syncytial Virus Infection in Mice and Its Mechanism].

T cell responses are elicited against Respiratory Syncytial Virus in the absence of signalling through TLRs, RLRs and IL-1R/IL-18R

Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons

Tissue-Resident Memory T Cells in the Lungs Protect against Acute Respiratory Syncytial Virus Infection

Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection

Differential Role of Anti-Viral Sensing Pathway for the Production of Type I Interferon β in Dendritic Cells and Macrophages Against Respiratory Syncytial Virus A2 Strain Infection

RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs

Combined blockade of IFN-Type I and TNF alpha receptors provides protection against respiratory syncytial virus (RSV)-induced disease and bronchoconstriction

Caspase-1 independent viral clearance and adaptive immunity against mucosal respiratory syncytial virus infection

Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection

Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus-induced lung airway obstruction (113.8)

Prevention of respiratory virus transmission by resident memory CD8+ T cells

Crucial role for IPS-1 signaling in mediating anti-viral responses and clearance of Respiratory Syncytial Virus (170.4)

MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection

Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung

The CD4 T cell response to respiratory syncytial virus infection

Inflammatory conditions shape phenotypic and functional characteristics of lung-resident memory T cells

Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review

How RSV Proteins Join Forces to Overcome the Host Innate Immune Response